Welcome to LookChem.com Sign In|Join Free

CAS

  • or

5400-79-3

Post Buying Request

5400-79-3 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

5400-79-3 Usage

Description

Ethyl 3-oxocyclopentane-1-carboxylate is an organic ester compound derived from cyclopentane carboxylic acid. It is characterized by its ester functional group, which provides it with unique chemical properties and reactivity. ethyl 3-oxocyclopentane-1-carboxylate is known for its potential applications in various industries, particularly in the pharmaceutical sector.

Uses

Used in Pharmaceutical Industry:
Ethyl 3-oxocyclopentane-1-carboxylate is used as a pharmaceutical intermediate for the synthesis of various drugs and medications. Its unique chemical structure allows it to serve as a key building block in the development of new pharmaceutical compounds, contributing to the advancement of medical treatments.
Used in Chemical Synthesis:
In the field of organic chemistry, ethyl 3-oxocyclopentane-1-carboxylate is utilized as a versatile reagent in the synthesis of a wide range of chemical products. Its ester functionality enables it to participate in various chemical reactions, making it a valuable component in the creation of diverse chemical compounds.
Used in Research and Development:
Ethyl 3-oxocyclopentane-1-carboxylate is also employed in research and development settings, where it is used to study the properties and behavior of ester compounds. Its unique structure and reactivity make it an interesting subject for scientific investigation, potentially leading to new discoveries and innovations in the field of chemistry.

Check Digit Verification of cas no

The CAS Registry Mumber 5400-79-3 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 5,4,0 and 0 respectively; the second part has 2 digits, 7 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 5400-79:
(6*5)+(5*4)+(4*0)+(3*0)+(2*7)+(1*9)=73
73 % 10 = 3
So 5400-79-3 is a valid CAS Registry Number.

5400-79-3 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail
  • Aldrich

  • (JWP00021)  3-Oxo-cyclopentanecarboxylic acid ethyl ester  AldrichCPR

  • 5400-79-3

  • JWP00021-1G

  • 2,575.17CNY

  • Detail

5400-79-3SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 17, 2017

Revision Date: Aug 17, 2017

1.Identification

1.1 GHS Product identifier

Product name Ethyl 3-oxocyclopentanecarboxylate

1.2 Other means of identification

Product number -
Other names ethyl 3-oxocyclopentane-1-carboxylate

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:5400-79-3 SDS

5400-79-3Relevant articles and documents

Biocatalytic synthesis of chiral cyclic γ-oxoesters by sequential C-H hydroxylation, alcohol oxidation and alkene reduction

Brenna, Elisabetta,Crotti, Michele,Gatti, Francesco G.,Monti, Daniela,Parmeggiani, Fabio,Pugliese, Andrea,Tentori, Francesca

, p. 5122 - 5130 (2017/11/09)

A three-step biocatalytic procedure is described for the conversion of methyl and ethyl cyclopentene- and cyclohexenecarboxylates into both the enantiomers of the corresponding chiral 3-oxoesters, which are useful building blocks for the synthesis of active pharmaceutical ingredients. The allylic hydroxylation of the starting cycloalkenecarboxylates is carried out by using R. oryzae resting cells entrapped in alginate beads, in acetate buffer solution at 25 °C. The oxidation of the intermediate allylic alcohols to unsaturated ketones, performed by the laccase/TEMPO system, and the ene-reductase mediated hydrogenation of the alkene bond were carried out in the same reaction vessel in a sequential mode at 30 °C. Being entirely biocatalytic, our multistep procedure provides considerable advantages in terms of selectivity and environmental impact over reported chemical methods.

Biocatalytic access to nonracemic γ-oxo esters: Via stereoselective reduction using ene-reductases

Turrini, Nikolaus G.,Cioc, Rǎzvan C.,Van Der Niet, Daan J. H.,Ruijter, Eelco,Orru, Romano V. A.,Hall, Mélanie,Faber, Kurt

, p. 511 - 518 (2017/08/14)

The asymmetric bioreduction of α,β-unsaturated γ-keto esters using ene-reductases from the Old Yellow Enzyme family proceeds with excellent stereoselectivity and high conversion levels, covering a broad range of acyclic and cyclic derivatives. Various strategies were employed to provide access to both enantiomers, which are versatile precursors of bioactive molecules. The regioselectivity of hydride addition on di-activated alkenes was elucidated by isotopic labeling experiments and showed strong preference for the keto moiety as activating/binding group as opposed to the ester. Finally, chemoenzymatic synthesis of (R)-2-(2-oxocyclohexyl)acetic acid was achieved in high ee on a preparative scale combining enzymatic reduction followed by ester hydrogenolysis.

POLYFLUORINATED COMPOUNDS ACTING AS BRUTON TYROSINE KINASE INHIBITORS

-

Paragraph 0443; 0444, (2016/08/17)

Described herein is a novel series of multi-fluoro-substituted pyrazolopyrimidine compounds or salts thereof. These compounds are Bruton's tyrosine kinase (BTK) inhibitors. These compounds may possess better BTK inhibition selectivity and pharmacokinetic properties. Disclosed herein are the synthesis methods of these compounds. Disclosed herein are novel synthesis methods of the multi-fluoro-substituted benzophenone and substituted phenoxy benzene. Also disclosed are pharmaceutical compositions comprising the BTK inhibitors described herein. The present invention also relates to pharmaceutical formulations comprising the compounds described herein as active ingredients. The present invention also includes the therapeutic methods by administering the BTK inhibitors and their formulations to treat and inhibit autoimmune disease, hypersensitivity disease, inflammatory diseases and cancer.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 5400-79-3